Cargando…

Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience

AIM OF THE STUDY: To determine the outcome of concomitant treatment of chronic hepatitis C virus (HCV) in children with malignant disease. MATERIAL AND METHODS: This was a prospective cohort study conducted at a gastroenterology and hepatology outpatient clinic in a children’s welfare teaching hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibraheem, Mohammad Fadhil, Ghali, Hasanein Habeeb, Kareem, Falah Hasan, Alqazaz, Ali Duraid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850300/
https://www.ncbi.nlm.nih.gov/pubmed/36683872
http://dx.doi.org/10.5114/ceh.2022.122278
_version_ 1784872153203605504
author Ibraheem, Mohammad Fadhil
Ghali, Hasanein Habeeb
Kareem, Falah Hasan
Alqazaz, Ali Duraid
author_facet Ibraheem, Mohammad Fadhil
Ghali, Hasanein Habeeb
Kareem, Falah Hasan
Alqazaz, Ali Duraid
author_sort Ibraheem, Mohammad Fadhil
collection PubMed
description AIM OF THE STUDY: To determine the outcome of concomitant treatment of chronic hepatitis C virus (HCV) in children with malignant disease. MATERIAL AND METHODS: This was a prospective cohort study conducted at a gastroenterology and hepatology outpatient clinic in a children’s welfare teaching hospital/medical city complex, Baghdad, from January 2018 to October 2020 and included 30 child and adolescent patients who contracted HCV while receiving treatment for malignant diseases. Data collected included those of medical history, physical examination, and periodic clinical and laboratory evaluation during their follow-up. Their age (at the time of diagnosis of HCV) ranged between 3.2 and 15.3 years, the mean age was 8.3 years, with male predominance of 60%. RESULTS: Sustained virologic response at post-treatment week 12 (SVR12) was obtained in all patients, 30/30 (100%), with gradual dramatic improvements of the liver enzymes, TSB, serum creatinine, and serum albumin. No serious side effects were registered, nor was there any treatment discontinuation or death. Tiredness was the most common side effect 10/30 (33.3%) in all patients. CONCLUSIONS: A combination of the ledipasvir plus sofosbuvir regimen for 12 weeks is effective and well tolerated, and can be used safely in treating children older than 3 years and adolescent patients with chronic hepatitis C.
format Online
Article
Text
id pubmed-9850300
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-98503002023-01-20 Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience Ibraheem, Mohammad Fadhil Ghali, Hasanein Habeeb Kareem, Falah Hasan Alqazaz, Ali Duraid Clin Exp Hepatol Original Paper AIM OF THE STUDY: To determine the outcome of concomitant treatment of chronic hepatitis C virus (HCV) in children with malignant disease. MATERIAL AND METHODS: This was a prospective cohort study conducted at a gastroenterology and hepatology outpatient clinic in a children’s welfare teaching hospital/medical city complex, Baghdad, from January 2018 to October 2020 and included 30 child and adolescent patients who contracted HCV while receiving treatment for malignant diseases. Data collected included those of medical history, physical examination, and periodic clinical and laboratory evaluation during their follow-up. Their age (at the time of diagnosis of HCV) ranged between 3.2 and 15.3 years, the mean age was 8.3 years, with male predominance of 60%. RESULTS: Sustained virologic response at post-treatment week 12 (SVR12) was obtained in all patients, 30/30 (100%), with gradual dramatic improvements of the liver enzymes, TSB, serum creatinine, and serum albumin. No serious side effects were registered, nor was there any treatment discontinuation or death. Tiredness was the most common side effect 10/30 (33.3%) in all patients. CONCLUSIONS: A combination of the ledipasvir plus sofosbuvir regimen for 12 weeks is effective and well tolerated, and can be used safely in treating children older than 3 years and adolescent patients with chronic hepatitis C. Termedia Publishing House 2022-12-28 2022-12 /pmc/articles/PMC9850300/ /pubmed/36683872 http://dx.doi.org/10.5114/ceh.2022.122278 Text en Copyright © 2022 Clinical and Experimental Hepatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Ibraheem, Mohammad Fadhil
Ghali, Hasanein Habeeb
Kareem, Falah Hasan
Alqazaz, Ali Duraid
Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
title Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
title_full Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
title_fullStr Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
title_full_unstemmed Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
title_short Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience
title_sort effectiveness of sofosbuvir/ledipasvir in hepatitis c virus infection in children and adolescents with malignancy: tertiary center experience
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850300/
https://www.ncbi.nlm.nih.gov/pubmed/36683872
http://dx.doi.org/10.5114/ceh.2022.122278
work_keys_str_mv AT ibraheemmohammadfadhil effectivenessofsofosbuvirledipasvirinhepatitiscvirusinfectioninchildrenandadolescentswithmalignancytertiarycenterexperience
AT ghalihasaneinhabeeb effectivenessofsofosbuvirledipasvirinhepatitiscvirusinfectioninchildrenandadolescentswithmalignancytertiarycenterexperience
AT kareemfalahhasan effectivenessofsofosbuvirledipasvirinhepatitiscvirusinfectioninchildrenandadolescentswithmalignancytertiarycenterexperience
AT alqazazaliduraid effectivenessofsofosbuvirledipasvirinhepatitiscvirusinfectioninchildrenandadolescentswithmalignancytertiarycenterexperience